CD69 Monoclonal Antibody (FN50), eBioscience™, Invitrogen™

Description

• Description: The FN50 monoclonal antibody reacts with human CD69, also known as very early activation antigen (VEA)
• CD69 is approximately 30 kDa and is expressed on the cell-surface as a disulfide-linked dimer
• CD69 is rapidly upregulated upon activation and expressed on lymphocytes, monocytes and platelets
• Applications Reported: The FN50 antibody has been reported for use in flow cytometric analysis and immunohistochemical staining
• Applications Tested: The FN50 antibody has been tested by flow cytometric analysis of resting and 6-hour TPA-activated human normal human peripheral blood cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD69 (AIM, Active Inducer Molecule) is a gp28/34 disulfide bonded homodimer with a molecular weight of 60 kDa under non-reducing conditions
• CD69 contains one or two N linked oligosacaride and the molecule is present on activated platelets
• In normal peripheral blood a variable percentage of cells express the CD69 antigen, and it is involved in lymphocyte signal transduction
• Expression CD69 is induced upon activation of T lymphocytes, and may play a role in proliferation
• Furthermore, the protein may act to transmit signals in natural killer cells and platelets
• Alternative splicing results in multiple transcript variants of CD69
• Diseases associated with CD69 dysfunction include coccidiodomycosis and asthma.